Q1 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript
Key Points
- Sun Pharmaceuticals Industries Ltd (BOM:524715) reported a 10.1% increase in sales for Q1 FY26, reaching INR 1,37,861 million.
- The company's EBITDA grew by 19.2% year-over-year, with an EBITDA margin of 31.1%.
- The India business saw a robust growth of 13.9%, with the company maintaining its number one market position.
- The US business experienced growth driven by the innovative medicines portfolio, including the successful launch of Lexelvi for severe alopecia areata.
- Sun Pharmaceuticals Industries Ltd (BOM:524715) continues to invest in R&D, with a focus on building a pipeline for both generics and innovative medicines, accounting for 6.5% of sales.
- The US generics business faced a decline due to increased competition in certain products.
- Exceptional items, including impairment charges, impacted the financial results, with a total of INR 880 million accounted for in the quarter.
- The effective tax rate increased to 24.3% from 16.1% in the previous year, affecting net profit growth.
- The company faces ongoing challenges with FDA compliance at certain manufacturing facilities, which could impact future approvals.
- There is continued pricing pressure in the US generics market, particularly affecting products like lanollunomide.
Ladies and gentlemen, good day and welcome to Sun Farmers Q1 F 526 earnings conference call. As a reminder, all participant clients will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the call, please signal an operator by pressing 0 on your touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Dr. Abhisheikh Sharma, Vice President and head of investor relations and strategic projects.
Thank you and over to you, sir.
Thank you. Good evening and a warm welcome to our first quarter F5 26 earnings call.
I'm Abhishek from the Sun Parma Investor relations team.
We hope you have received the Q1 financials and the press release that was sent out earlier in the day. These are also available on our website. We have with us Mr. Gilli Shagui, Chairman and managing director, Mr. Kihi Gankar, CEO India Business, and MD
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
